EL7.AI
StocksMedium•17 November 2026•
3 min read

REPLENISH Data Show Sustained Remission in 41.2% With Cosentyx at 300 mg

Key Facts

1Sustained remission was 41.2% with 300 mg, 40.6% with 150 mg, and 20.4% with placebo at Week 52.
2The mean annualized cumulative adjusted glucocorticoid dose was 1604 mg and 1683 mg with Cosentyx, compared with 2093 mg with placebo.
3The REPLENISH trial included three treatment groups and a prednisone taper over 24 weeks.
4The Phase III REPLENISH trial was conducted in 27 countries.

The available evidence does not reliably confirm U.S. approval of Cosentyx for polymyalgia rheumatica on November 17, 2026; therefore, the approval news in the draft cannot be attributed to the U.S. Food and Drug Administration. Available information centers on results from the REPLENISH trial announced by Novartis on June 3, 2026. At Week 52, sustained remission was achieved by 41.2% of patients who received 300 mg and 40.6% of those who received 150 mg, compared with 20.4% with placebo. These figures put both Cosentyx arms ahead of the control group on the sustained remission measure. The company said all primary and secondary endpoints were met in both treatment arms, and no new safety signals were observed among participating patients with polymyalgia rheumatica.

Remission results were also associated with a lower mean annualized cumulative adjusted glucocorticoid dose in both Cosentyx groups. Novartis estimated the mean at 1604 mg with the 300 mg dose and 1683 mg with the 150 mg dose, compared with 2093 mg with placebo, according to Week 52 results. This measure shows cumulative glucocorticoid exposure during the results period, alongside the sustained remission measure. The company reported all three figures as part of the same trial data. It also said the primary and secondary endpoints were met with both doses, with no new safety signals observed in patients who received Cosentyx.

REPLENISH tested three treatment groups: Cosentyx at 300 mg, Cosentyx at 150 mg, and placebo, with prednisone tapered over 24 weeks in all three groups. According to Novartis, the study was a global, randomized, double-blind, placebo-controlled Phase III trial conducted in 27 countries. Its design compares the results for the two drug doses with a group that received placebo under the same steroid-tapering regimen. The company announced the trial data on June 3, 2026. The results were published in the New England Journal of Medicine and presented concurrently at the 2026 EULAR Congress, according to the announcement.

The disease occurs against a treatment backdrop reliant on steroids, according to Novartis, which said available treatment for polymyalgia rheumatica had relied on their long-term use. The company added that relapse may affect up to 40% of patients during the first year, and that long-term steroid use, as the standard of care, carries significant risks. Novartis describes polymyalgia rheumatica as a common inflammatory rheumatic disease in adults aged 50 years and older. Its usual symptoms include severe pain and stiffness in the shoulders, neck and hips. This context links the remission results and glucocorticoid doses in REPLENISH to the problem of relapse and long-term steroid exposure, without by itself establishing a treatment effect beyond the trial.

The European Commission had previously approved Cosentyx for adults with polymyalgia rheumatica on October 21, 2026, according to Novartis. The European approval covered patients who did not respond adequately to glucocorticoids or relapsed while tapering their dose. The company said at the time that additional regulatory reviews of the drug for the disease were ongoing in the United States and Japan. The recommended adult dose in the European Union is 150 mg by subcutaneous injection, with initial doses in weeks 0, 1, 2, 3 and 4, followed by a monthly maintenance dose. The company added that the maintenance dose may be increased to 300 mg depending on clinical response, alongside glucocorticoid tapering.

Open on chart